WAM
OMED

Wealthspire Advisors (Maryland)’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-34
Closed – – 2763
2017
Q4 		$0 Hold
34
– – ﹤0.01% 2672
2017
Q3 		$0 Hold
34
– – ﹤0.01% 2649
2017
Q2 		$0 Buy
+34
New +$141 ﹤0.01% 2386

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s OMED Position: Q1 2018 in Review

Wealthspire Advisors (Maryland) sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2018, closing a stake of 34 shares.

Wealthspire Advisors (Maryland) first reported a position in OMED in Q2 2017 and held it in 3 quarters. The position peaked at $0 in Q4 2017. 66 funds tracked by Wall St. Rank hold OMED as of Q1 2018.

  • Wealthspire Advisors (Maryland) reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 34 OncoMed Pharmaceuticals, Inc. shares in Q1 2018.
  • Wealthspire Advisors (Maryland) first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2017 and held it in 3 quarters.
  • Wealthspire Advisors (Maryland)'s OncoMed Pharmaceuticals, Inc. position peaked at $0 in Q4 2017.
  • 66 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2018.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q1 2018, filed 3 May 2018.